Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned ( @:@ ) to @ cycles maximum ( @ days/cycle ) of pemetrexed @mg/m ( @ ) + cisplatin @mg/m ( @ ) ( day @ ) , or gemcitabine @mg/m ( @ ) ( days @ and @ ) + cisplatin @mg/m ( @ ) ( day @ ) .